UNITY BIOTECHNOLOGY, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.49 USD | +2.05% |
|
-2.61% | -22.80% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 331.2 | 277.3 | 84.28 | 38.89 | 32.39 | 25.01 | - | - |
| Enterprise Value (EV) 1 | 293.8 | 179.6 | 17.67 | -35.54 | -10.81 | 16.57 | 42.77 | 70 |
| P/E ratio | - | - | -1.34 x | -0.43 x | -0.71 x | -0.76 x | -0.78 x | -1.12 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | 17.6 x | 165 x | - | - | - | 1.46 x |
| EV / Revenue | - | - | 3.69 x | -151 x | - | - | - | 4.08 x |
| EV / EBITDA | -3.38 x | -1.98 x | -0.33 x | 0.64 x | - | -0.47 x | -0.86 x | -1.32 x |
| EV / FCF | - | - | -390,372 x | 695,180 x | 291,275 x | - | - | - |
| FCF Yield | - | - | -0% | 0% | 0% | - | - | - |
| Price to Book | 2.82 x | 3.37 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,594 | 5,291 | 5,772 | 14,192 | 16,785 | 16,787 | - | - |
| Reference price 2 | 72.10 | 52.40 | 14.60 | 2.740 | 1.930 | 1.490 | 1.490 | 1.490 |
| Announcement Date | 3/11/20 | 3/23/21 | 3/15/22 | 3/15/23 | 4/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 4.784 | 0.236 | - | - | - | 17.15 |
| EBITDA 1 | -86.99 | -90.48 | -53.78 | -55.39 | - | -35.24 | -49.72 | -53.07 |
| EBIT 1 | -89.65 | -93.93 | -56.66 | -57.57 | -44.67 | -34.63 | -37.97 | -33.34 |
| Operating Margin | - | - | -1,184.47% | -24,394.92% | - | - | - | -194.43% |
| Earnings before Tax (EBT) 1 | - | - | -60.72 | -59.93 | -39.86 | -32.97 | -37.65 | -32.97 |
| Net income 1 | - | - | -60.72 | -59.93 | -39.86 | -32.97 | -37.65 | -32.97 |
| Net margin | - | - | -1,269.34% | -25,392.8% | - | - | - | -192.24% |
| EPS 2 | - | - | -10.90 | -6.310 | -2.700 | -1.952 | -1.908 | -1.330 |
| Free Cash Flow | - | - | -45.26 | -51.12 | -37.1 | - | - | - |
| FCF margin | - | - | -945.97% | -21,663.14% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/11/20 | 3/23/21 | 3/15/22 | 3/15/23 | 4/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 4.784 | - | 0.236 | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -7.372 | -8.464 | -9.105 | -9.799 |
| EBIT 1 | -9.898 | -18.27 | -12.26 | -13.13 | -13.92 | -10.65 | -11.96 | -14.93 | -7.677 | -7.599 | -8.379 | -8.899 | -9.456 |
| Operating Margin | -206.9% | - | -5,194.07% | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -10.69 | -18.92 | -13.14 | -13.71 | -14.17 | -10.86 | -12.2 | -15.29 | -4.339 | -5.79 | -8.135 | -8.662 | -9.213 |
| Net income 1 | -10.69 | -18.92 | -13.14 | -13.71 | -14.17 | -10.86 | -12.2 | -15.29 | -4.339 | -5.79 | -8.135 | -8.662 | -9.213 |
| Net margin | -223.52% | - | -5,566.53% | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -1.800 | -2.800 | -1.900 | -1.360 | -1.000 | -0.7600 | -0.8500 | -1.050 | -0.2800 | -0.3400 | -0.4800 | -0.5097 | -0.5401 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/15/22 | 5/10/22 | 8/12/22 | 11/8/22 | 3/15/23 | 5/9/23 | 8/8/23 | 11/13/23 | 4/15/24 | 5/14/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | 17.8 | 45 |
| Net Cash position 1 | 37.5 | 97.7 | 66.6 | 74.4 | 43.2 | 8.45 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | -0.3571 x | -0.8478 x |
| Free Cash Flow | - | - | -45.3 | -51.1 | -37.1 | - | - | - |
| ROE (net income / shareholders' equity) | -58.4% | -92.3% | -85.3% | -94.8% | -94.4% | -249% | -292% | -92.6% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 25.60 | 15.60 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.59 | 0.65 | 0.2 | 0.1 | 0.01 | 0.65 | 0.65 | 0.65 |
| Capex / Sales | - | - | 4.08% | 40.68% | - | - | - | 3.79% |
| Announcement Date | 3/11/20 | 3/23/21 | 3/15/22 | 3/15/23 | 4/15/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.49
USD
Average target price
6
USD
Spread / Average Target
+302.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.80% | 24.51M | |
| +9.99% | 114B | |
| +12.01% | 107B | |
| -3.07% | 22.22B | |
| -0.67% | 21.28B | |
| -4.64% | 18.8B | |
| -6.90% | 17.51B | |
| -39.36% | 17.17B | |
| +5.82% | 14.14B | |
| +33.05% | 12.2B |
- Stock Market
- Equities
- UBX Stock
- Financials Unity Biotechnology, Inc.
